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Abstract
We are in the midst of a pandemic due to the novel coronavirus SARS-CoV-2. Innovative therapies are in the lookup
around the world. Recently, chloroquine and hydroxychloroquine in addition to azithromycin were proposed to be used
in patients with severe disease even though strong evidence
is lacking. We propose the use of tetracyclines in addition to
anti-virals early in the curse of the disease in order to prevent
the cytokine storm syndrome associated with COVID-19 and
prevent ARDS. The proposed mechanisms of tetracyclines
are: 1) anti-apoptotic properties; 2) decrease the Myeloperoxidase and ROS releaser from immune cells; 3) decrease

neutrophil and monocyte migration and chemotaxis; 4) decrease the secretion of pro-inflammatory and vasoactive cytokines from macrophages (IL-1 beta, IL-8, and TNF-alpha);
5) inhibition of iNOS expression; 6) inhibition of chemotaxis of
peripheral monocytes; 7) inhibition of IL-6 production and its
receptor system; 8) prevention of fibrosis; and 9) inhibition of
metalloproteinases (particularly MMP-2 and 9). Tetracyclines
are well-known drugs with lower costs, and are not associated with adverse effects like QT prolongation. Clinical trials
are needed to test our hypothesis.

Introduction

tality after some positive results in a study in France
where a rapid fall of nasopharyngeal viral loads tested
by qPCR was noted, with 83% negative at Day 7, and 93
% at Day 8.[3] The number of patients presumably contagious (with a PCR Ct value <34) steadily decreased
over time and reached zero on Day 12.[4] The FDA approved an emergency use authorization (EUA) of this
drug under the directives of the President. On April 4,
2020, the FDA recommended against the combination
of CQ or HCQ with Azithromycin outside clinical trials
and in the outpatient settings due to lack of convincing
clinical evidence of its effectivity and serious concerns
about cardiac toxicity like QT prolongation when used
in combination.[5]

We are in the midst of a pandemic caused by the novel
coronavirus SARS-CoV-2 (named by WHO on Feb 11,
2020).[1] A recent Morbidity and Mortality Weekly
Report (MMWR) revealed that among 44 cases with
known outcome, 15 (34%) deaths were reported among
adults aged ≥85 years, 20 (46%) among adults aged
65–84 years, and nine (20%) among adults aged 20–
64 years.[2] Case-fatality percentages increased with
increasing age, from no deaths reported among persons aged ≤19 years to highest percentages (10%–27%)
among adults aged ≥85 years. Some reports showed
deaths in the group of <19 years of age, but it is
rare. The number of cases is trending up globally and
healthcare systems are being overwhelmed in certain
regions. Of note, the mortality is significantly higher
than with seasonal influenza.[1, 2] Innovative therapies are in the lookup around the world in international academic centers until an effective and safe vaccine is available. Recently, chloroquine (CQ) and hydroxychloroquine (HCQ) were proposed to be used in
COVID-19 patients with the goal of decreasing mor-
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The FDA also issued an EUA on May 5, 2020 for the
investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID19 in adults andchildren hospitalized with severe disease.[6]
The most common cause of mortality due SARS-CoV-2
(as well as with SARS-CoV-1 and MERS-CoV) is acute
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respiratory distress syndrome (ARDS).[1, 2, 7, 8] The
objective of this review is to explore the possible role
of tetracyclines on decreasing the mortality observed
with SARS-CoV-2 as an immunomodulator targeting
the COVID-19-associated-CSS/ARDS. We extrapolated
data from the previous outbreak of SARS-CoV-1, for
which there is extensive documentation and is phylogenetically related to COVID-19.
Pathogenesis and histopathology of SARS-CoV-1 and
SARS-CoV-2: similarities With influenza-associated-ARDS
Some common features were seen in the histopathology of SARS-CoV-1, MERS, and SARS-CoV-2).[1, 7]
We will call these 3 related viral pathogens highly
pathogenic human coronavirus (HPHCoV). COVID-19
is a systemic disease since ACE-2 receptors (SARS-CoV2’s receptor) are located in multiple tissues including
lung epithelial lining, vascular endothelial cells (arterial and venous), and the mucosal cells of the intestines,
epithelial cells of the renal tubules, cerebral neurons
and immune cells.[9] The main target of SARS-CoV2, however, is the lung, which is driving mortality.
Due to the paucity of data from COVID-19 autopsies
at the time of preparation of this manuscript, we will
describe mainly the histopathology findings seen during the SARS-CoV-1 outbreak in 2002 for which there is
much more data.
In the lung tissue from autopsies of HPHCoV usually
there are extensive hyaline membrane formation, interstitial infiltration with lymphocytes and mononuclear cells, Giant cells with markers of macrophages,
and desquamation of pneumocytes in the alveolar
space. Macroscopically patchy areas of lung consolidation and edema, pleural effusions, focal hemorrhages, and mucopurulent material in the tracheobronchial tree are usually seen. Diffuse alveolar damage (DAD) is common being septal and alveolar fibrosis expectable in later stages.[8] Microscopically, viral particles can be seen not only in type 1 and 2
pneumocytes [7] but also on the airway and alveolar epithelial cells, vascular endothelial cells, monocytes and lymphocytes and macrophages.[8] Multiple cellular infiltrates were observed including neutrophils and macrophages (predominance of activated
macrophages). The peripheral cell count usually shows
lymphopenia, which may reflect active lymphocytic recruitment to the lungs, induced-apoptosis, or selective suppression of lymphocytes precursors in the bone
marrow. Activated monocytes and lymphocytes in the
lung tissue may recruit, orchestrate, and exacerbate
the inflammatory activity of neutrophils, showing a
connection between adaptive and innate immune responses. In animal models of SARS-CoV-1, there is initially a massive recruitment of pathogenic inflammatory monocyte-macrophages (IMMs), which cause further self-accumulation and local release of TNF, IL-6,
IL1-β, and iNOS.[8] IMMs induce lymphocyte apopto-
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sis with decreased viral clearance and promotion of local viral persistence. SARS-CoV-1 infection of Dendritic
cells (DCs) and macrophages induces up-regulation
of pro-inflammatory cytokines like TNF, IL-6, and a
significant up-regulation of inflammatory chemokines
CCL3, CCL5, CCL2, and CXCL10. The elevation of
Interferon is mild which impairs viral clearance (evasion of innate immune system). Severe SARS-CoV-1
patients had significantly higher serum levels of proinflammatory cytokines (IFN-γ, IL-1, IL-6, IL-12, and
TGFβ) and chemokines (CCL2, CXCL10, CXCL9, and
IL-8) compared with SARS-CoV-1 patients with mild
disease.[8] Interestingly, in very sick patients the antiinflammatory cytokine IL-10 was decreased. There are
no studies showing the role of metalloproteinase in
SARS-CoV-1/2 associated-ARDS. All the above can explain the cytokine storm syndrome (CSS) documented
in severe cases of SARS-CoV-1, which also applies to
COVID-19 cases.
In summary, there is evidence showing a dysregulated
immune response with an exuberant inflammatory disease, evasion of the immune response (through inhibition of Interferon molecules), and disseminated direct
cytopathic effects.[8] ARDS is a common final event
that leads to death. Interestingly, the ARDS seems to
occur once the viral titers drop, which means that most
of the tissue damage is probably immune-mediated. It
looks like monocytes-macrophages and neutrophils are
the ultimate culprit that drive the local inflammatory
cytokine storm and tissue damage.
The consequences of the overwhelming immune response are: 1) epithelial and endothelial apoptosis
with vascular leakage; 2) decreased SARS-CoV-1/2
specific T-cell immune responses due to the exuberant immune response with T-cell apoptosis (and high
titer viral replication); and 3) persistent activation of
macrophages, neutrophils, and fibroblasts (with lung
fibrosis).
Analogy with influenza-associated-ARDS
The mortality associated with influenza pneumonia is
also attributed to ARDS.[10] Making an analogy of a
possible common mechanism of lung-tissue damage
between HPHCoVs and influenza brings up the possible role of metalloproteinases (“Gelatinasas”). During influenza pneumonia, histopathological features revealed a prominent neutrophilic infiltration within the
affected areas implicating their primary role in lung
injury. These activated neutrophils cause local release of toxic granular products such as matrix metalloproteinases (MMPs), myeloperoxidase (MPO), elastase,
and reactive oxygen intermediates (ROI) contributing
to lung injury. Gelatinases (including MMP-2 and
MMP-9), which are zinc-dependent endopeptidases,
affects the components of the basement membranes
such as gelatin and collagen IV, and the epithelium
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and endothelium in the alveolar-capillary barrier. The
above mechanism accounts for the intense increased
permeability and exudation into the alveolar space
seen during ARDS with thickening of the alveolararterial space and refractory hypoxemia. There may
be multiple similarities between some final events that
leads to death between HPHCoVs and severe influenza
pneumonia since in both there is an intense lung infiltration of macrophages-neutrophils, which may release
MMPs along with ROS.
Tetracyclines, the molecule: anti-inflammatory properties
and its possible role in SARS-CoV-2-associated-ARDS
Our group performed an extensive review of tetracyclines when we proposed to use this molecule to decrease the accelerated aging process of well-controlled
HIV patients of ART.[11] We will review their antiinflammatory and immunomodulatory properties of
this molecules applied to HPHCoV models.
First discovered in the 1950s by screening organisms
obtained from the soil while looking for new antibiotics (Streptomyces aureofaciens produced chlortetracycline, trade name Aureomycin), it was clear that
tetracyclines not only had anti-infective but also antiinflammatory properties as well. Since then, tetracyclines (especially the new second generation’s tetracyclines like doxycycline and minocycline) have been
extensively used for non-infectious disease processes
such as rosacea, bullous dermatoses, neutrophilic
diseases, pyoderma gangrenosum, sarcoidosis, aortic
aneurysms, cancer metastasis, periodontitis; autoimmune diseases such as rheumatoid arthritis, hidradenitis suppurativa, and scleroderma; and COPD.[12-26]
The anti-inflammatory properties of tetracyclines are as
follows (see also Table 1).
(1) It was shown that tetracyclines have anti-apoptotic
properties because they inhibit the caspase 1 and
3 pathways along with decreasing the cytochrome
c release from the mitochondria.[16] This is important since T-cell CD4+ cell lymphopenia was seen in
COVID-19 patients. Decreasing the apoptosis of lymphocytes is extremely important to mount an early specific CD4 and CD8 immune response against SARSCoV-2 infected cells to control the initial high viral
replication and avoid local viral persistence. The decrease in apoptosis may also involve the T-cell suppressor subtype, which may help control the exuberant immune activation. The suppression of apoptosis
would also prevent the epithelial and endothelial induced apoptosis, which exacerbates vascular leakage,
micro thrombosis, and further inflammation-exudation
to the alveolar and vascular space.
(2) On in vitro models in rats, tetracyclines not only decreased the Myeloperoxidase (MPO) release from neuULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/9
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trophils but the neutrophil migration as well.[27] Of
note, the prolonged MPO persistence on tissues may
predispose to local oxidative stress and, hence, extend
the local inflammatory process even further. The same
group described that minocycline and doxycycline also
decrease the carrageenan-induced paw edema in rat
models, which may be related to the fact that tetracyclines decrease the secretion of pro-inflammatory and
vasoactive cytokines reducing the increase permeability associated with acute and chronic inflammation. On
the same animal models, tetracyclines showed not only
antioxidant properties but inhibition of iNOS expression as well.[26] Decreasing chemotaxis, secretion of
pro-inflammatory cytokines, vascular leakage, and local oxidative stress could be extremely important to
prevent COVID-19-associated ARDS/CSS.[10]
(3) A classic effect of these classes of molecules is that
they decrease the secretion of pro-inflammatory cytokines from macrophages (IL-1 beta, IL-8, and TNFalpha) in response to stimulation with LPS, which
points towards an important inhibitory mechanism
on the innate immune system. In postmenopausal
women with periodontitis, low-dose doxycycline lowered markers of systemic inflammation such as hs-CRP,
myeloperoxidase (MPO), MMP-8, TIMP-1, MMP-9,
MMP-2, IL-6, TNF-a, and IL-1b.[14, 28] In a SIV model,
minocycline treatment decreased the pro-inflammatory
CD14+CD16+ monocytes, and reduced their expression of CD11b, CD163, CD64, CCR2 and HLA-DR
along with a decrease of IL-6 production by monocytes following LPS stimulation.[15] Tetracyclines also
inhibit the chemotaxis of peripheral monocytes to the
activated endothelium since the production of vascular endothelial growth factor (VEGF), and hence, of
MCP-1, is decreased.[29, 30] It has been shown that
minocycline not only suppress IL-6 production, but
also its receptor system and signaling pathways.[31]
Tetracyclines also suppress hydrolases, such as phospholipase A2, which is an important enzyme that mediates activation of inflammatory mediators such as
prostaglandins.[32] Since COVID-19-associated-ARDS
is driven by an exuberant immune response (CSS) orchestrated by recruited activated monocytes and neutrophils, doxycycline could be important in controlling the local over-activation of the innate immune system. In addition, decreasing the production of TNF
by activated macrophages may decrease the apoptosis
of lymphocytes which looks like is TNF-driven.[8] Of
note, inhibition of IL-6 is the mechanism of action of
tocilizumab, which is being evaluated currently in clinical trials for COVID-19.
(4) Fibrosis is the culmination of many types of chronic
inflammatory processes and it can be either beneficial or harmful. Excessive fibrosis on tissues alters the normal homeostasis and functioning of organs. It has been seen that inflammation-inducedlymphangiogenesis (IIL) can be inhibited with doxycycline through suppression of VEGF-C signaling.[33]
3
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Table 1. Characteristics of tetracyclines and interruption of inflammatory pathways.

Properties of tetracyclines

Consequences

• Increase lymphocyte count (lymphocytes)
Anti-apoptotic properties

• Decrease vascular leakage (endothelium)
• Decrease alveolar exudation (epithelium)

Decrease chemotaxis and migration of innate immune cells

• Decreased local release of MPO, ROS, and MMP

Decreased secretion of
pro-inflammatory cytokines
from activated
macrophages

• Decrease of immune-activation
• Decreased recruitment of immune cells
• Decreased duration and intensity of the CSS
• Decreased ARDS

Inhibition of IL-6 and its pathway

• Highly involved on CSS (Tocilizumab)
• Decreased degradation of alveolar-capillary membrane

Inhibition of MMP 2/9

• Decreased alveolar exudation and leakage
• Improve lung histology

Anti-fibrotic properties

• Decrease the progression to lung fibrosis
• Decrease sequela

It is well known that under some circumstances,
macrophages can switch to a pro-angiogenic phenotype (or M2-type), which predisposes some patients to
neovascular age-related macular degeneration and certain cancers. It has been shown that doxycycline can
function as an adjuvant anti-angiogenic agent since it
can decrease the switching of macrophages from M1 to
the M2 phenotype.[34] On this case Doxycycline may
prevent the late stages of HPHCoVs-associated-ARDS
on which fibrosis represents the last stage. Neovascularization may also play a role as part of the alveolar
hemorrhage seen in previous SARS-CoV-1 infections
and that may apply to COVID-19 as well. Of note, the
distortion of the lung architecture due to fibrosis may
also impair the local immune response in order to clear
the remaining viral particles. It may be extremely important to prevent fibrosis since it may define if the patient will develop chronic lung disease after the acute
episode.
(5) In a model of burn-induced microvascular hyperpermeability (typical example of acute inflammation),
it was seen that the edema and extravasation was attenuated with doxycycline.[35] This could be important
in the context of HPHCoVs-associated-apoptosis of epithelial and endothelial cells with vascular leakage and
extravasation of fluid to the alveoli and interstitial tissue. On this case tetracyclines may provide some relief
to the refractory hypoxemia and alveolar collapse seen
in the worse (lethal) cases of COVID-19.
(6) One of the most well-known anti-inflammatory
properties of tetracyclines is the inhibition of metalloULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/9

proteinases (MMP) [36]—particularly MMP-2 and 9—
which has been the focus of intense research recently,
applied not only to chronic gingivitis models and
COPD [13, 14, 17, 18, 21, 24, 35] but to cardiovascular
disease, [37] left ventricular remodeling, [38] and arterial aneurysm progression.[17] The accumulated MMP2 and MMP-9 can aggravate pulmonary damage by
degrading the basement membranes of the alveoli.[10]
Not only neutrophils but also activated macrophages
synthesize MMP-2 and MMP-9 de novo, and these proteinases play a role in macrophage-dependent acute
lung injury (ALI). It has been documented that the
lung of patients with SARS-CoV-1 shows massive
macrophage infiltration.[6] If the histopathology of
COVID-19 resembles what happens with SARS-CoV1 and influenza pneumonia, the inhibition of MMPs
2-9 with tetracyclines may be extremely important
in controlling the final events that leads to ARDS.
A recent study in H3N2-infected mice showed significantly decreased expression and activities of both
MMP-2 and MMP-9 after Doxycycline treatment.[8]
The above mechanism would avoid the macrophage
and/or neutrophil-associated damage due to local release of not only MMPs but reactive oxygen species
(ROS) as well. Paraquat (PQ) is a nonselective herbicide that has been widely used and its effect resembles
what happens in viral-induced ARDS with intense neutrophilic infiltration and release of MMPs. A recent animal study showed that doxycycline could significantly
inhibit the overexpression of MMP9 induced by PQ
administration in both lung tissues and BALs. Doxycycline reduced neutrophil infiltration, markedly sup-
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pressed the levels of pro-inflammatory cytokines, local
MPO release, and even improved the histological characteristics of the lung.[39] This is important since ARDS
is the result of multiple insults (chemical or infectious)
with common histopathological features that could be
reversed with tetracyclines.
Possible adverse reactions to tetracyclines
(1) Tetracyclines have also been involved in decreasing
the inflammatory response through the immunomodulatory effects on T-cells. This is the main reason of their
use on T-cell mediated diseases like rheumatoid arthritis and other autoimmune diseases that are mainly Tcell mediated.[12, 26] In the early 1990’s, investigators had already documented these immunomodulatory effects on T-cells as a novel mechanism of action that needed to be explored.[40] It was suggested
that doxycycline might decrease the inflammatory reaction in some autoimmune diseases by eliminating
activated T lymphocytes through the known process
of Fas/FasL-mediated apoptosis.[41] In the case of
HPHCoVs-induced-ARDS, there is already a decrease
number of lymphocytes not clearly explained. Further
decrease of the lymphocyte function may impair the
control of viral replication and promote local viral persistence. At the same time, tetracyclines may control
the cytokine storm, which may be the culprit of lymphocyte apoptosis. The net effect will need to be seen
in experimental or human clinical trials.
(2) Nausea, vomiting, abdominal pain, and esophagitis may be seen in patients exposed to this drug class
when taken orally, which may impair the absorption of
other medications in non-intubated patients.
(3) Clostridium difficile colitis is also possible but less
like with tetracyclines than with other antibiotics (such
as cephalosporins, quinolones, and clindamycin) but
some degree of dysbiosis is expectable.

Conclusions
There are only two drugs approved under EUA to
treat COVID-19 patients with severe disease as dis-
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cussed above. HCQ has questionable effectivity and
can cause cardiac toxicity mainly when used in combination with Azithromycin. Definitively there is no
evidence to use concomitant Azithromycin and is not
recommended by multiple medical societies outside
Clinical trials. Remdesivir showed decreased time to
recovery compared with a control group without statistically significant benefit in terms of mortality.[6]
New innovative, effective, and safe therapies are highly
needed. Tetracyclines are well-known, inexpensive
drugs that have been used for decades, and have an
acceptable adverse effect profile. Tetracyclines have
many anti-inflammatory properties that, theoretically,
could work as an immunomodulator counteracting the
exuberant inflammatory response triggered by HPHCoVs (including COVID-19). Some of the proposed
mechanisms could include: decrease apoptosis of lymphocytes, endothelial, and epithelial cells; decrease the
migration of neutrophils and monocytes; decrease the
secretion of pro-inflammatory cytokines (including IL6) and chemokines; decrease oxidative stress and release of ROS; inhibition of the activity of the metalloproteinases (MMP-2/9); and decrease in the progression to lung fibrosis. A direct anti-viral (either CQ,
HCQ, or Remdesivir) will need to be used along with
tetracyclines so it will be guaranteed the control of the
viral replication and the immune response that was
triggered. The combination will need to be used early
in the course of the disease since during late stages (established CSS/ARDS/fibrosis) may be very difficult to
reverse. Probably every patient admitted to the hospital with pneumonia has had already viral replication for some time (even while asymptomatic) and may
present with early CSS, which is the optimal time to
start an anti-viral (to treat remaining virions) and an
immunomodulator. The intersection between decrease
of viral titers and increase of cytokine release is difficult to define. This theoretical model will need to be
proven in animal studies or in prospective randomized
controlled clinical trials. A question that remains unanswered is if the addition of zinc to HCQ or CQ may be
detrimental since it is a well-known cofactor of MMPs
and super oxide dismutase (SOD) both of which promotes endothelial oxidative stress.
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